Share This Page
Drug Price Trends for NDC 57664-0951
✉ Email this page to a colleague
Average Pharmacy Cost for 57664-0951
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| DEXTROAMPH-AMPHET ER 25 MG CAP | 57664-0951-88 | 8.53325 | EACH | 2025-12-17 |
| DEXTROAMPH-AMPHET ER 25 MG CAP | 57664-0951-88 | 8.49387 | EACH | 2025-11-19 |
| DEXTROAMPH-AMPHET ER 25 MG CAP | 57664-0951-88 | 8.47961 | EACH | 2025-10-22 |
| DEXTROAMPH-AMPHET ER 25 MG CAP | 57664-0951-88 | 8.52218 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 57664-0951
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 57664-0951
Introduction
The National Drug Code (NDC) 57664-0951 corresponds to a specific pharmaceutical product registered and regulated by the Food and Drug Administration (FDA). Precise insights into its market dynamics, competitive landscape, and pricing require detailed evaluation. This analysis provides an in-depth review of current market positioning, demand trends, pricing strategies, competitive environment, and future price projections for this drug.
Product Overview and Therapeutic Context
NDC 57664-0951 is associated with [Manufacturer Name]’s [Drug Name], a [indication] therapy approved for [patient population]. The drug's mechanism involves [describe mechanism], targeting [specific pathway/condition]. It is primarily used for [primary indications], with off-label applications emerging based on recent clinical data.
The drug's therapeutic landscape fits within the broader category of [therapeutic class], which includes [list relevant competitors]. The increasing prevalence of [disease/condition] and advancements in [related treatments/technologies] influence market demand and pricing parameters.
Market Size & Demand Dynamics
Current Market Landscape
According to IQVIA data, the U.S. market for [indication] therapies amounted to approximately $X billion in 2022, with a compound annual growth rate (CAGR) of X% over the past five years. The segment’s growth is driven by increased diagnosis rates and expanded indications.
[Drug Name] holds an estimated X% market share among its direct competitors. Its sales volumes have increased owing to [factors such as] favorable clinical trial results, expanded approvals, and heightened physician adoption.
Regulatory and Market Penetration
The drug received FDA approval in [year], with subsequent label expansions in [years] enhancing its target patient population. Its market penetration varies geographically; for example, in the U.S., it commands significant share, while in Europe and Asia, adoption remains in earlier phases due to regulatory and pricing negotiation hurdles.
Emerging Market Opportunities
Growing markets include [list regions such as Asia-Pacific, Latin America], where the rising burden of [relevant diseases] and increasing healthcare infrastructure create opportunities. Challenges include regulatory barriers, reimbursement complexities, and local pricing controls.
Competitive Environment
The competitive landscape encompasses [list of key competitors], offering branded or biosimilar options. Comparative advantages of [Drug Name] involve [notable attributes such as efficacy, safety profile, administration route, patent exclusivity].
Patent protections are critical; [specific patent expiration date or patent litigations] potentially open opportunities for biosimilar entrants or generic manufacturing. Patent expiry typically correlates with significant price erosion, affecting long-term revenue projections.
Several biosimilars or alternative therapies have entered the market, creating pricing pressures. However, the brand’s established clinical reputation preserves some pricing power, particularly if it demonstrates superior efficacy or safety.
Pricing Analysis and Trends
Current Price Point
As of Q1 2023, the average wholesale acquisition cost (WAC) for [Drug Name] stands at $X per unit/dose. This pricing reflects factors such as development costs, exclusivity, therapeutic value, and market demand.
Pricing Drivers
- Regulatory Status: FDA approval and any exclusivity periods sustain higher prices.
- Market Penetration and Adoption: Increased acceptance supports stable or rising prices.
- Reimbursement Trends: Payer negotiations influence ultimate net prices; managed care prefers cost-effective options.
- Manufacturing Costs: Raw material prices, complexities of production, and supply chain stability directly impact drug pricing margins.
Pricing Trends and Historical Data
Historically, similar drugs have experienced X% annual price increases, often driven by inflation, R&D costs, and competitive dynamics. The advent of biosimilars typically induces price reductions of Y% within 3-5 years post patent expiry.
Future Price Projections
Forecast Based on Market Trends
Analysts project that the price of [Drug Name] will [increase/decrease/stabilize] over the next 3-5 years. Key influencing factors include:
- Patent lifecycle progression, with potential biosimilar entries expected by [year].
- Expansion into new geographic and therapeutic markets.
- Payer negotiations and reform policies aimed at cost containment.
- Innovation in formulation or delivery mechanisms, potentially enabling premium pricing.
Scenario Analysis
- Optimistic Scenario: Continued clinical success, regulatory approvals, and minimal biosimilar competition could sustain or modestly grow drug pricing, with projections reaching $Y per dose by [year].
- Pessimistic Scenario: Early biosimilar entry, aggressive price competition, and increased price regulation could reduce prices by up to Z%, averaging $A per dose.
Regulatory and Market Access Outlook
Pricing strategies will be shaped by ongoing negotiations with payers and regulatory agencies. A positive market access environment enhances pricing power, while reimbursement constraints may suppress net prices. The shift toward value-based arrangements emphasizes clinical outcomes, potentially rewarding premium pricing for superior efficacy or safety profiles.
Key Factors Influencing Future Price Trajectory
- Patent expiry timelines
- Biosimilar development pipeline
- Regulatory landscape changes
- Competitive positioning and differentiation
- Healthcare policy reforms
Conclusion
The current market for [Drug Name] demonstrates a moderate to high growth trajectory, supported by clinical demand, expanding indications, and patent protection. While current pricing maintains a premium compared to biosimilars, impending patent expirations and market entry of alternatives threaten price stability. Strategic positioning, clinical validation, and robust payer negotiations are critical for optimizing future pricing outcomes.
Key Takeaways
- Market size for [indication] therapies is expanding, bolstered by diagnosis growth and emerging markets.
- Competitive landscape remains intense, with patent protections shielding pricing power temporarily.
- Current average wholesale prices suggest a premium positioning based on clinical value.
- Future price projections depend heavily on patent expiries, biosimilar entries, and health policy reforms.
- Proactive market access strategies and continuous innovation are vital for maintaining profitability.
FAQs
1. When is the patent protection for NDC 57664-0951 expected to expire?
Patent expiration details depend on jurisdiction-specific filings; typically, patents last 20 years from filing, with extensions possible. Exact dates should be confirmed through patent databases or manufacturer disclosures.
2. How will biosimilar competition impact the price of [Drug Name]?
Biosimilar market entry usually leads to significant price reductions, often 20-35%, within 3-5 years post patent expiry, pressuring the innovator’s pricing strategies.
3. Are there any regulatory challenges that could affect the price trajectory?
Yes. Policies focusing on drug price controls, value-based approval pathways, or stricter reimbursement criteria may influence pricing and market access.
4. Which regions represent the highest growth potential for this drug?
Emerging markets within Asia-Pacific, Latin America, and parts of Europe offer promising growth due to rising disease burden and expanding healthcare infrastructure.
5. What are the key factors driving current pricing strategies for this drug?
Clinical efficacy, safety profile, market exclusivity, manufacturing costs, and payer negotiations primarily determine the current pricing approach.
References
- IQVIA Institute. “The Global Use of Medicines in 2022.”
- FDA Regulations and Patent Data.
- Market Reports from [industry-specific sources], 2022-2023.
- Healthcare Policy Analyses, 2022.
- Patent databases and biosimilar development pipelines (e.g., Patentscope, Orange Book).
More… ↓
